The stock market rebounded on Monday to regain losses from a slow start to the year.
NASDAQ led the indices, which grew 2.2% to 14,844, boosted by tech stocks that dropped last week. Meanwhile, S&P 500 was up 1.4% to 4,764.
Tweet of the Day
You can’t make this up
Tesla ended 2023 at exactly 4.20% market share.
(Source: Kelly Blue Book) pic.twitter.com/p2NuWXyr3K
— Car Dealership Guy (@GuyDealership) January 8, 2024
Chart of the Day
Here is the ten-year chart of Merck (MRK) as of December 20, 2023, when the stock was at $105.
Merck reported strong performance, particularly in its Human Health business, which sustained strong momentum with revenue growth of 10%. This was primarily driven by the success in the oncology and vaccines segments. Keytruda, Merck’s flagship product, experienced significant expansion in the United States fueled by increased utilization in both metastatic indications and earlier-stage cancers. Merck’s vaccines portfolio delivered strong growth, with Gardasil sales up 16% driven by strong demand in China. However, in the US, Gardasil sales experienced a decrease due to purchasing patterns by the Centers for Disease Control and Prevention (CDC).
MRK is part of the Conservative Growth Portfolio.
